Bristol Taxol Kaposi's sarcoma labeling cites increased toxicity with higher recommended dose.
Executive Summary
TAXOL KAPOSI's SARCOMA LABELING NOTES GREATER TOXICITY WITH HIGHER DOSE used in the Phase II studies of the Bristol-Myers Squibb paclitaxel product. In clinical trials for AIDS-related Kaposi's sarcoma patients, "135 mg/m2 every three weeks was more toxic" than 100 mg/m2 every two weeks and "all the patients with low performance status were treated with the latter schedule," labeling notes. The indication was approved Aug. 4 ("The Pink Sheet" Aug. 11, T&G-1).
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth